Screener
Syndax Pharmaceuticals SNDX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other receivable | 6,137 | 45 |
| Accounts payable | (5,737) | (1,579) |
| Accrued expenses and other liabilities | (28,349) | (2,533) |
| Net cash used in operating activities | (50,345) | (95,162) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of short and long-term investments | (39,387) | (10,538) |
| Proceeds from sales and maturities of short-term investments | 77,777 | 104,680 |
| Net cash provided by investing activities | 38,390 | 94,142 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's operating cash flow?
- Syndax Pharmaceuticals (SNDX) reported operating cash flow of -$50.35M in Q1 2026.
- How has Syndax Pharmaceuticals's operating cash flow changed year-over-year?
- Syndax Pharmaceuticals's operating cash flow increased by 47.1% year-over-year, from -$95.16M to -$50.35M.
- What is the long-term trend for Syndax Pharmaceuticals's operating cash flow?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's operating cash flow has grown at a 82.5% compound annual growth rate (CAGR), from $29.13M to -$322.98M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Syndax Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude